Under a tenth of people that would benefit from obesity jabs such as Wegovy have access to them, caution the World Health Organization as it publishes its inaugural advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is urging broader and more equitable access to GLP-1 medication.
Based on projections, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"The latest guidelines acknowledges that obesity is a long-term condition that can be addressed with holistic and lifelong treatment," said its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are significant obstacles to widespread access to the jabs that can help people shift considerable body mass, explains the body.
Skinny Jab Supply Crisis
Even under the present best projected case, the production of these medications would only suffice for about 100 million people – fewer than 10% of those who need them, as stated by the health organization.
The recommendation encourages countries and companies to widen availability, through strategies like licensing agreements.
A patent on the active ingredient – the main ingredient of a leading brand – is due to expire in a number of nations in 2026.
The Way Weight-Loss Jabs Work
The injections imitate a body's own hormone to delay gastric emptying, curb appetite and increase satiety so people consume fewer calories.
Patients typically see weight reduction in the initial weeks of starting on the once-weekly jabs.
Evidence suggests people may see weight return within a year of discontinuing the drug, because their usual food cravings return.
Being carrying excess weight increases your risk for contracting health problems, like type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight impacts individuals in all nations and was linked to 3.7 million fatalities worldwide in 2024, according to the WHO.
